ACHIEVE LIFE SCIENCES, INC.
Business
Achieve Life Sciences is a specialty pharmaceutical company developing cytisinicline, a naturally occurring alkaloid for nicotine dependence treatment in smoking and e-cigarette cessation. The company has completed Phase 3 trials for smoking cessation and Phase 2 for vaping cessation, with an NDA submitted to the FDA. Cytisinicline is licensed for exclusive development and commercialization outside territories where Sopharma markets it as Tabex.
Summary from 10-K filed 2026-03-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total operating expenses | 55 | 39 | 27 | 41 | 33 | |
| Interest income | 1 | 2 | 825,000 | 199,000 | 17,000 | |
| Interest expense [note 8] | −819,000 | −2 | −3 | −2 | — | |
| Change in fair value of contingent consideration [note 5 and note 6] | −408,000 | −621,000 | −528,000 | — | — | |
| Loss on extinguishment of 2023 SVB convertible term loan [note 8] | — | −283,000 | — | — | — | |
| Other income (expense) | −36,000 | −30,000 | −9,000 | 40,000 | −75,000 | |
| Total other income (expense) | 232,000 | −758,000 | −3 | −2 | −58,000 | |
| Net Loss | −55 | −40 | −30 | −42 | −33 | |
| Net unrealized gain (loss) on securities | −21,000 | 27,000 | — | — | — | |
| Total other comprehensive income (loss) | −21,000 | 27,000 | — | — | — | |
| Comprehensive loss | −55 | −40 | −30 | −42 | — | |
| Basic net loss per common share [note 10 [i]] | −1.25 | −1.24 | −1.5 | −4 | −4.08 | |
| Diluted net loss per common share [note 10 [i]] | −1.25 | −1.24 | −1.5 | −4 | −4.08 | |
| Shares used in computation of basic net loss per common share [note 10 [i]] | 44 | 32 | 20 | 11 | 8 | |
| Shares used in computation of Diluted net loss per common share [note 10 [i]] | 44 | 32 | 20 | 11 | 8 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents [note 3 and note 6] | 21 | 13 | 16 | 25 | 43 | |
| Marketable securities [note 6] | 15 | 22 | — | — | — | |
| Total current assets | 40 | 36 | 17 | 27 | 45 | |
| Restricted cash and other assets [note 6 and note 7] | 52,000 | 39,000 | 92,000 | 66,000 | 183,000 | |
| Right-of-use assets [note 12] | 64,000 | 119,000 | 66,000 | 123,000 | 64,000 | |
| License agreement [note 4 and note 5] | 751,000 | 974,000 | 1 | 1 | 2 | |
| Goodwill | 1 | 1 | 1 | 1 | 1 | |
| Total assets | 42 | 39 | 19 | 30 | 48 | |
| Accrued clinical liabilities | 368,000 | 1 | 280,000 | 2 | 1 | |
| Accrued compensation | 2 | 3 | 2 | 2 | 2 | |
| Current contingent consideration [note 5 and note 6] | 2 | 0 | 528,000 | — | — | |
| Current portion of long-term obligations [note 12] | 61,000 | 55,000 | 63,000 | 58,000 | 69,000 | |
| Current portion of convertible debt [note 6 and note 8] | 4 | — | 17 | 16 | — | |
| Total current liabilities | 9 | 7 | 21 | 22 | 5 | |
| Non-current portion of convertible debt [note 6 and note 8] | 11 | 10 | — | — | 15 | |
| Non-current contingent consideration [note 5 and note 6] | 0 | 1 | — | — | — | |
| Long-term obligations [note 12] | 5,000 | 66,000 | 6,000 | 69,000 | 4,000 | |
| Total liabilities | 20 | 18 | 21 | 22 | 19 | |
| Commitments and contingencies [note 12] | — | — | — | — | — | |
| Common stock, $0.001 par value, 150,000,000 shares authorized, 53,233,988 and 34,685,072 issued and outstanding at December 31, 2025 and December 31, 2024, respectively. | 121,000 | 103,000 | 90,000 | 87,000 | 79,000 | |
| Additional paid-in capital | 282 | 226 | 164 | 144 | 122 | |
| Accumulated deficit | −260 | −206 | −166 | −136 | −94 | |
| Accumulated other comprehensive income | 10,000 | 31,000 | 4,000 | 4,000 | 4,000 | |
| Total stockholders' equity | 22 | 21 | −1 | 8 | 28 | |
| Total liabilities and stockholders' equity | 42 | 39 | 19 | 30 | 48 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −55 | −40 | −30 | −42 | −33 | |
| Depreciation and amortization [note 4] | 228,000 | 229,000 | 228,000 | 236,000 | 250,000 | |
| Stock-based compensation [note 10[c], note 10[d], note 10[e]] and note 10[f]] | 9 | 5 | 3 | 3 | 2 | |
| Shares issued as settlement with trade vendor | 0 | — | 273,000 | 26,000 | 41,000 | |
| Accrued interest on SVB convertible debt [note 8] | 0 | 799,000 | 1 | 1 | — | |
| Amortization of 2024 SVB convertible term loan transaction costs [note 8] | 52,000 | 23,000 | — | — | — | |
| Accretion of discount on modification of debt [note 8] | — | 365,000 | 430,000 | — | — | |
| Grant receivable | — | 111,000 | −6,000 | 48,000 | −153,000 | |
| Accrued clinical liabilities | −709,000 | 797,000 | −1 | 376,000 | 899,000 | |
| Accrued compensation | −1 | 716,000 | 633,000 | −263,000 | 466,000 | |
| Lease obligation | 0 | −1,000 | −58,000 | −5,000 | −14,000 | |
| Net cash used in operating activities | −50 | −30 | −24 | −38 | −29 | |
| Proceeds from exercise of warrants [note 10[g]] | 1 | 682,000 | 227,000 | 24,000 | 338,000 | |
| Proceeds from employee stock purchase plan [note 10[e]] | 0 | 178,000 | — | 126,000 | — | |
| Taxes paid related to net share settlement of equity awards | 0 | −114,000 | −220,000 | −47,000 | — | |
| Proceeds from June 2025 public offering exercise of overallotment option, net of issuance costs [note 10b] | 4 | — | — | — | — | |
| Repayment of 2023 SVB convertible term loan [note 6 and note 8] | — | −18 | — | — | — | |
| Receipt of 2024 SVB convertible term loan less transaction costs [note 6 and note 8] | — | 10 | — | — | 15 | |
| Receipt of 2024 SVB convertible term loan second tranche [note 6 and note 8] | 5 | — | — | — | — | |
| Net cash provided by financing activities | 52 | 49 | 15 | 19 | 37 | |
| Purchase of property and equipment | −3,000 | — | −21,000 | — | — | |
| Loss on disposal of property and equipment | −1,000 | — | — | — | — | |
| Realized gain on investments | 4,000 | — | — | — | — | |
| Purchase of investments | −25 | −48 | — | — | — | |
| Maturities of investments | 31 | 26 | — | — | — | |
| Net cash provided by (used in) investing activities | 6 | −22 | −21,000 | — | — | |
| Effect of exchange rate changes on cash | 3,000 | — | −3,000 | 3,000 | −1,000 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 8 | −3 | −9 | −18 | 7 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ACHIEVE LIFE SCIENCES, INC.'s CIK number?
ACHIEVE LIFE SCIENCES, INC.'s SEC CIK number is 0000949858 (949858). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ACHIEVE LIFE SCIENCES, INC.'s SEC filings?
All of ACHIEVE LIFE SCIENCES, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did ACHIEVE LIFE SCIENCES, INC. last report earnings?
ACHIEVE LIFE SCIENCES, INC. (ACHV) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-218175). This is ACHIEVE LIFE SCIENCES, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is ACHIEVE LIFE SCIENCES, INC.'s most recent earnings 8-K?
ACHIEVE LIFE SCIENCES, INC.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-218175. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View ACHIEVE LIFE SCIENCES, INC.'s latest earnings 8-K →
Look up any company's CIK number →